

ATOMIC ENERGY CANCER HOSPITAL BINOR (AECH-BINOR), BANNU
Pakistan Bait-ul-Maal (PBM) & Zakat Medicine Tender Documents

TERMS & CONDITIONS

1. The validity of tender shall be for the period of financial year 2026-27, extendable by two additional months with mutual consent.
2. The supply will be made at BINOR, Bannu within seventy two (72) hours of the receipt of supply order, as and when required by BINOR.
3. Tender will be based on single stage 02 envelope Process (1. Technical & 2. Financial).
4. Quotation must be accompanied with at least 2% call deposit of the total quoted value or Rs.200,000/- where the quantity is not mentioned, in favor of HLAO, BINOR Bannu. Quotation received without earnest money will not be considered for competition. The amount of call deposit will be returned to the un-successful bidders after finalization of the case.
5. The medicine will be purchased from supplier through BINOR Patients Welfare Society (BPWS) i.e. BPWS will raise supply order and arrange stocking and issuance of the medicines to the patients. Payment will also be made through BPWS to the supplier.
6. The supplier/firm having bad reputation/blacklisted with any government Organization etc. may not apply at all.
7. The firms which fail to supply the store up to the requisite quantity, quality and specification within the delivery date/specified time, the purchaser will have the right to confiscate the earnest money/security sent along-with the quotation/tender and cancel the order/contract and purchase the store elsewhere at risk and cost of the firm which fails to supply for which no notice shall be issued and the purchaser will not be responsible for any loss that firm may suffer due to the cancellation of the order/contract, or in such a case the purchaser may either impose a penalty on firm to be paid by the firm by the way of liquidated damages at the rate of 0.5 to 2% of the value of un-supplied store per day for the number of days by which the delivery is delayed and beyond the said date/specified time up to a maximum of 10% of the total contract value.
8. Taxes as per government rules shall also be deducted.
9. The competent authority reserves the right to accept or reject any quotation /tender or part thereof without assigning any reason in writing.
10. Only those medicines will be supplied which have the maximum expiry date available in the market, preferably not less than 70% of its shelf life. BINOR reserves the right to


Administrator

ATOMIC ENERGY CANCER HOSPITAL BINOR (AECH-BINOR), BANNU
Pakistan Bait-ul-Maal (PBM) & Zakat Medicine Tender Documents

reject any or all the medicines which are not in accordance with our specifications/requirement, standard, quality, quantity or size contained in the supply order and supplier shall replace all the near expiry medicines with fresh stock at the cost of supplier.

11. The supplier will have to submit authorized dealership certificate from the concerned pharmaceutical companies at the time of tender.
12. Initially technical bids will be opened. Evaluation of the technical bids will be done as per standard criteria, given along with this document. Financial bids of the technically successful suppliers will be opened after evaluation of technical bids.
13. All medicines supplied shall be subject to the inspection by the inspection officer (Store)/Inspection Board of this Institute.
14. Any package discount offered by the manufacturer/supplier will also be available to BINOR.
15. Supplier shall produce necessary cheque acknowledgement receipt of payment made to them through crossed cheque.
16. Drugs list has been provided with tender documents. Each medicine in the list has been assigned a serial number. The serial numbers assigned in this list must be mentioned along with name of medicine while quoting its price. The rate submitted must be in terms of smallest unit price i.e. per tab, per capsule or per injection.
17. Any firm/party not agreeing with the above Terms & Conditions may not participate in the tender.


Administrator

S No	Medicines (Injections)	Stength
1	Inj-Ado-Trustuzumab Emtansine	100 mg
2	Inj-Ado-Trustuzumab Emtansine	160 mg
3	Inj-Atezolizumab	1200 mg
4	Inj-Azacitidine	100 mg
5	Inj-Bendamustine	100 mg
6	Inj-Bevacizumab	100 mg
7	Inj-Bevacizumab	400 mg
8	Inj-Bleomycin	15 IU
9	Inj-Bortezomib	2 mg
10	Inj-Bortezomib	3.5 mg
11	Inj-Cabazitaxel	60 mg
12	Inj-Camrelazumab	200 mg
13	Inj-Cituximab	100 mg
14	Inj-Carboplatin	150 mg
15	Inj-Carboplatin	450 mg
16	Inj-Cisplatin	50 mg
17	Inj-Cyclophosphamide (lyophilized)	1G
18	Inj-Cyclophosphamide	1G
19	Inj-Decitabine	50 mg
20	Inj-Decitabine	100 mg
21	Inj-Dacarbazine	200 mg
22	Inj-Daunorubicin	20 mg
23	Inj-Dactinomycine	0.5 mg
24	Inj-Denosumab	120mg (70mg) 12-8
25	Inj-Docetaxel	120 mg
26	Inj-Docetaxel	80 mg
27	Inj-Docetaxel	20 mg
28	Inj-Doxorubicin	50 mg
29	Inj-Epirubicin	50 mg
30	Inj-Etoposide	100 mg
31	Inj-Filgristim	300 MCG
32	Inj-Fludarabine	50 mg
33	Inj-Fluorouracil (5-FU)	500 mg
34	Inj-Fulvestrant	250 mg
35	Inj-Gemcitabine	200 mg
36	Inj-Gemcitabine	1G
37	Inj-Goserelin	3.6 mg
38	Inj-Topotecan	4 mg
39	Inj-Octeriotide LAR	30 mg
40	Inj-Ifosfamide	1G
41	Inj-Ifosfamide	2G
42	Inj-ifosfamide (lyophilized)	1G
43	Inj-Recombinant interleukin Eleven (IL-11)	1.5 mg
44	Inj-Recombinant interleukin Eleven (IL-11)	3 mg

[Handwritten signature]

[Handwritten signature]

45	Inj-Irinotecan	100 mg
46	Inj-Irinotecan	300 mg
47	Inj-Leucovorin Calcium (folinic acid)	50 mg
48	Inj-Leucovorin Calcium (folinic acid)	100 mg
49	Inj-Leuprorelin (Leoprolide)	3.75 mg
50	Inj-Leuprorelin (Leoprolide)	7.5 mg
51	Inj-Leuprorelin (Leoprolide)	11.25 mg
52	Inj-Liposomal Doxorubicin	20 mg
53	Inj-Methotrexate	50 mg
54	Inj-Mitomycin C	10 mg
55	Inj-Mesna	400 mg
56	Inj-Nevolumab	40 mg
57	Inj-Nevolumab	100 mg
58	Inj-Nab-Paclitaxel	100 mg
59	Inj-Obinutuzumab	1G
60	Inj-Oxaliplatin	50 mg
61	Inj-Oxaliplatin	100 mg
62	Inj-Onco BC6	40 mg
63	Inj-Paclitaxel	150 mg
64	Inj-Paclitaxel	300 mg
65	Inj-Pegfilgrastim	6 mg
66	Inj-Pemetrexed	100 mg
67	Inj-Pemetrexed	500 mg
68	Inj-Pertuzumab	420 mg
69	Inj-Polatuzumab Vedotin	140 mg
70	Inj-Pertuzumab+Trastuzumab (Combination)	1200+600 mg
71	Inj-Pertuzumab+Trastuzumab (Combination)	600+600 mg
72	Inj-Pembrolizumab	100 mg
73	Inj-Rituximab	100 mg
74	Inj-Rituximab	500 mg
75	Inj-Rituximab	1400 mg
76	Inj-Trastuzumab	440 mg
77	Inj-Trastuzumab	600 mg S/C
78	Inj-Vinblastine	10 mg
79	Inj-Vincristine	1 mg
80	Inj-Vincristine	2 mg
81	Inj-Vinorelbine	50 mg
82	Inj-Zoledronic acid	4mg

inj *of*

S No	Medicines (Tablets)	Stength
83	Tab-Abemaciclib	150 mg
84	Tab-Abiraterone acetate	250 mg
85	Tab-Afatinib	40 mg
86	Tab-Apalutamide	60 mg
87	Tab-Axitinib	5 mg
88	Tab-Bicalutamide	50 mg
89	Tab-Ceretinib	150 mg
90	Tab-Cabozatinib	20 mg
91	Tab-Capecitabine	500 mg
92	Tab-Dexatinib	50 mg
93	Tab-Eltrombopag	50 mg
94	Tab-Enzalutamide	40 mg
95	Tab-Enzalutamide	80 mg
96	Tab-Erlotinib	150 mg
97	Tab-Everolimus	10 mg
98	Tab-Flutamide	250 mg
99	Tab-Gefitinib	250 mg
100	Tab-Imatinib	100 mg
101	Tab-Imatinib	400 mg
102	Tab-Lenalidomide	10 mg
103	Tab-Lenalidomide	25 mg
104	Tab-Lenvatinib	4 mg
105	Tab-Letrozole	2.5 mg
106	Tab-Leucovorin Calcium (folinic acid)	15 mg
107	Tab-Niraparib	100 mg
108	Tab-Olaparib	150 mg
109	Tab-Osimertinib	80 mg
110	Tab-Palbociclib	125 mg
111	Tab-Pazopanib	400 mg
112	Tab-Pazopanib	1200 mg
113	Tab-Ponatinib	15 mg
114	Tab-Ponatinib	45 mg
115	Tab-Regorafenib	40 mg
116	Tab-Ruxolitinib	15 mg
117	Tab-Relugolix	120 mg
118	Tab-Thalidomide	100 mg
119	Tab-Suorafenib	200 mg
120	Tab-Sunitinib	50 mg
121	Tab-Temoxifen	10 mg
122	Tab-Temoxifen	20 mg
123	Tab-Temozomide	20 mg

ip

f

124	Tab-Temozomide	100 mg
125	Tab-Temozomide	250 mg
126	Tab-Tucatinib	150 mg
127	Tab-Trifluridine	6.14 mg
128	Tab-Trifluridine	15 mg
129	Tab-Venetoclax	100 mg

4300
PER LITRE

ip

[Signature]

S No	Medicines (Capsule)	Stength
130	Cap-Alectinib	150 mg
131	Cap-Crizotinib	250 mg
132	Cap-Ibrutinib	140 mg
133	Cap-Lomustine	40 mg
134	Cap-Nilotinib	150 mg
135	Cap-Nilotinib	200 mg
136	Cap-Pomalidomide	4 mg
137	Cap-Procarbazine	50 mg



Focal Person Zakat Cell BINOR
HWC Member



Marking Criteria

03

A. Technical (70 Marks)				
Sr. No	Parameters	Details	Maximum Grade	Remarks
1.	Product Registration	Category –A	40	
		1). US FDA 2). EMA (Europe source only) 3). MHRA UK 4). TGA Australia 5). PHARMAC, New Zealand 6). PMDA Japan 7). Swiss-Medics Switzerland 8). Health Canada 9). HAS Singapore 10). ANMAT Argentina		
		Category –B	30	
		1). ANVIZ Brazil 2). CDSCO India 3). NPCB Malaysia 4). FDA South Korea 5). MOH Egypt 6). MOH Turkey 7). FDA China 8). DRA Pakistan 9). any other Authorities not mentioned in category-A		
2.	Bio-availability/Bio equivalence/ Bio similar certificate.	Whatever and wherever applicable.	10	Original Innovator Product do not require bio equivalence/ bio similar certificate and shall get 10 marks automatically.
		NO Certificate.	0	
3.	Clinical Trial/ Clinical studies assessing the safety and efficacy of the quoted item is drug. In case if the quoted item is generic the studies must be performed on the generic and not on the originator. (Must be an original research article).	In case the study is published in journal listed in HEC Journal Recognition System (HJRS) Database.	5	DOI or article title page copy is mandatory to provide (both in soft and hard form) and mentioned in format form.
		In case the study is published in journal NOT listed in HEC Journal Recognition System (HJRS) Database	0	



Marking Criteria

04

4.	Cold Chain Facility	Certificate of compliance to cold chain standards issued by an authorized third party e.g. DRAP, PSQCA, and PCSIR.	5	The procurement entity reserve the right to visit any cold chain facility for physical inspection/ verification
		NON-Compliance to international reference standards or absence of cold chain requirement.	0	Disqualification
5.	Current GMP Certificate	Issued by authorities as mentioned in Category A above in sr. no. 1	5	Certificate should be attached with technical bid.
		Issued by authorities as mentioned in Category B above in sr. no. 1	2	
6.	Past Performance (Last two years)	<ul style="list-style-type: none"> • Agha Khan University Hospital Karachi. • Shaukat Kahanum Hospitals • Shifa International hospital Islamabad. • Atomic Energy Cancer Hospitals. 	5	Invoice proof clearly showing date and quantity of supply and also "Good performance Certificate" will be needed from the institute to which the supplies are made.
		Others	2	

B. Financial (30 marks)

1.	Financial Status: (The price quoted must be the lowest quoted anywhere in Pakistan in the previous twelve months. in case this is not done, the supplier is bound to refund the difference of the price to the procuring agency).	(Lowest Bid/Your Bid) × 30
----	---	-----------------------------------

Total Technical Score=70 Qualifying marks in technical: 45
Total Financial Score=30
Total Score: 100


Focal Person PBM/Zakat Fund BINOR

PUBLIC SECTOR ORGANIZATION TENDER NOTICE NO. 01/2026-27 BANNU, KPK

BINOR Cancer Hospital is interested in the purchase of Chemo Medicine out Pakistan Bait-Ul-Mal and Zakat Fund, for deserving cancer patients. All registered bidders are invited for participation in the bid through **single stage-two envelopes procedure** on "**as and when required F.O.R BINOR basis**".

Tender Documents can be obtained **free of cost** from the office of undersigned during working hours (08:00 AM to 02:30 PM).

Last date for submission of bids is **27.06.2026, 10:30 AM**. Bids will be opened on the same date at **11:00 AM sharp**.

ADMINISTRATOR

BINOR Cancer Hospital, Phase-II Bannu Township, District Bannu.
(Ph# 0928-633535, Fax# 0928-633485, Email# binor.bannu@gmail.com)



(Munirullah Khan)
Administrator